| Chlorine | Monitoring | N/A | N/A | Mar 31, 2025 | Resolved | Eye and nose irritation; stomach discomfort |
| Chlorine | Monitoring | N/A | N/A | Mar 31, 2025 | Resolved | Eye and nose irritation; stomach discomfort |
| Chlorine | Monitoring | N/A | N/A | Mar 31, 2025 | Resolved | Eye and nose irritation; stomach discomfort |
| Chlorine | Monitoring | N/A | N/A | Mar 31, 2025 | Resolved | Eye and nose irritation; stomach discomfort |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Mar 31, 2025 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Mar 31, 2025 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Mar 31, 2025 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Mar 31, 2025 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Mar 31, 2025 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.029 | Dec 31, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.029 | Dec 31, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.029 | Dec 31, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.029 | Dec 31, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.029 | Dec 31, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Dec 10, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Dec 10, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Dec 10, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Health-Based | N/A | N/A | Nov 20, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Health-Based | N/A | N/A | Nov 20, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Health-Based | N/A | N/A | Nov 20, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Health-Based | N/A | N/A | Nov 20, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Nov 10, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Nov 10, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Nov 10, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Nov 10, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Nov 10, 2024 | Resolved | N/A |
| E. COLI | Monitoring | 0 | N/A | Oct 15, 2024 | Resolved | Severe gastrointestinal illness; may be fatal in vulnerable populations |
| E. COLI | Monitoring | 0 | N/A | Oct 15, 2024 | Resolved | Severe gastrointestinal illness; may be fatal in vulnerable populations |
| E. COLI | Monitoring | 0 | N/A | Oct 15, 2024 | Resolved | Severe gastrointestinal illness; may be fatal in vulnerable populations |
| E. COLI | Monitoring | 0 | N/A | Oct 15, 2024 | Resolved | Severe gastrointestinal illness; may be fatal in vulnerable populations |
| E. COLI | Monitoring | 0 | N/A | Oct 15, 2024 | Resolved | Severe gastrointestinal illness; may be fatal in vulnerable populations |
| Arsenic | Health-Based | N/A | 0.031 | Sep 30, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.031 | Sep 30, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.031 | Sep 30, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.031 | Sep 30, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.031 | Sep 30, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Public Notice | Monitoring | N/A | N/A | Aug 21, 2024 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Aug 21, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Health-Based | N/A | N/A | Jul 9, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Health-Based | N/A | N/A | Jul 9, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Health-Based | N/A | N/A | Jul 9, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Health-Based | N/A | N/A | Jul 9, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 30, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 30, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 30, 2024 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.029 | Jun 30, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.029 | Jun 30, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.029 | Jun 30, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Jun 30, 2024 | Resolved | N/A |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Jun 30, 2024 | Resolved | N/A |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Jun 30, 2024 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.029 | Jun 30, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.029 | Jun 30, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.029 | Jun 30, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Monitoring | N/A | N/A | Jun 30, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Monitoring | N/A | N/A | Jun 30, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Monitoring | N/A | N/A | Jun 30, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Monitoring | N/A | N/A | Jun 30, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Monitoring | N/A | N/A | Jun 30, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Monitoring | N/A | N/A | Jun 30, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 10, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 10, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 10, 2024 | Resolved | N/A |
| E. COLI | Monitoring | 0 | N/A | Jun 8, 2024 | Resolved | Severe gastrointestinal illness; may be fatal in vulnerable populations |
| E. COLI | Monitoring | 0 | N/A | Jun 8, 2024 | Resolved | Severe gastrointestinal illness; may be fatal in vulnerable populations |
| E. COLI | Monitoring | 0 | N/A | Jun 8, 2024 | Resolved | Severe gastrointestinal illness; may be fatal in vulnerable populations |
| E. COLI | Monitoring | 0 | N/A | Jun 8, 2024 | Resolved | Severe gastrointestinal illness; may be fatal in vulnerable populations |
| E. COLI | Monitoring | 0 | N/A | Jun 8, 2024 | Resolved | Severe gastrointestinal illness; may be fatal in vulnerable populations |
| Arsenic | Health-Based | N/A | 0.03 | Mar 31, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.03 | Mar 31, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.03 | Mar 31, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.03 | Mar 31, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.03 | Mar 31, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Nitrate | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | Infants below the age of six months could become seriously ill (blue baby syndrome); shortness of breath |
| Nitrate | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | Infants below the age of six months could become seriously ill (blue baby syndrome); shortness of breath |
| Nitrate | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | Infants below the age of six months could become seriously ill (blue baby syndrome); shortness of breath |
| Tetrachloroethylene | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | Liver problems; increased risk of cancer |
| Vinyl chloride | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | Increased risk of cancer |
| Carbon tetrachloride | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | Liver problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.032 | Dec 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.032 | Dec 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| p-Dichlorobenzene | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| p-Dichlorobenzene | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| p-Dichlorobenzene | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| Carbon tetrachloride | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | Liver problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.032 | Dec 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.032 | Dec 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.032 | Dec 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Carbon tetrachloride | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | Liver problems; increased risk of cancer |
| Carbon tetrachloride | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | Liver problems; increased risk of cancer |
| Vinyl chloride | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | Increased risk of cancer |
| Vinyl chloride | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | Increased risk of cancer |
| Vinyl chloride | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | Increased risk of cancer |
| Tetrachloroethylene | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | Liver problems; increased risk of cancer |
| p-Dichlorobenzene | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| Tetrachloroethylene | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | Liver problems; increased risk of cancer |
| Tetrachloroethylene | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | Liver problems; increased risk of cancer |
| Dinoseb | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| Dinoseb | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| Dinoseb | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| Dinoseb | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| Pentachlorophenol | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| Pentachlorophenol | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| Pentachlorophenol | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| Pentachlorophenol | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| 1,2,4-Trichlorobenzene | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| 1,2,4-Trichlorobenzene | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| 1,2,4-Trichlorobenzene | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| 1,2,4-Trichlorobenzene | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| cis-1,2-Dichloroethylene | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| cis-1,2-Dichloroethylene | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| cis-1,2-Dichloroethylene | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| cis-1,2-Dichloroethylene | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| Xylenes, Total | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| Xylenes, Total | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| Xylenes, Total | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| Xylenes, Total | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| DICHLOROMETHANE | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| DICHLOROMETHANE | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| DICHLOROMETHANE | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| DICHLOROMETHANE | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| o-Dichlorobenzene | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| o-Dichlorobenzene | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| o-Dichlorobenzene | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| o-Dichlorobenzene | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| 1,1-Dichloroethylene | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| 1,1-Dichloroethylene | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| 1,1-Dichloroethylene | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| 1,1-Dichloroethylene | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| trans-1,2-Dichloroethylene | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| trans-1,2-Dichloroethylene | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| trans-1,2-Dichloroethylene | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| trans-1,2-Dichloroethylene | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| 1,2-Dichloroethane | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| 1,2-Dichloroethane | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| 1,2-Dichloroethane | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| 1,2-Dichloroethane | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| 1,1,1-Trichloroethane | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| 1,1,1-Trichloroethane | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| 1,1,1-Trichloroethane | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| 1,1,1-Trichloroethane | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| 1,2-Dichloropropane | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| 1,2-Dichloropropane | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| 1,2-Dichloropropane | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| 1,2-Dichloropropane | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| Styrene | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| Styrene | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| Styrene | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| Styrene | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| Combined Uranium | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| Combined Uranium | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| Combined Uranium | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| Combined Uranium | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| Trichloroethylene | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | Liver problems; increased risk of cancer |
| Chlorine | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | Eye and nose irritation; stomach discomfort |
| Toluene | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| Toluene | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| Toluene | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| Ethylbenzene | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| Trichloroethylene | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | Liver problems; increased risk of cancer |
| Trichloroethylene | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | Liver problems; increased risk of cancer |
| Ethylbenzene | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| Ethylbenzene | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| 2,4-D | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| 2,4-D | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| 2,4-D | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| Toluene | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| Ethylbenzene | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| Trichloroethylene | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | Liver problems; increased risk of cancer |
| CHLOROBENZENE | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| CHLOROBENZENE | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| CHLOROBENZENE | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| CHLOROBENZENE | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| Picloram | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| Picloram | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| Picloram | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| Picloram | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| 2,4,5-TP | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| 2,4-D | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| 2,4,5-TP | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| 2,4,5-TP | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| 1,1,2-Trichloroethane | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| 1,1,2-Trichloroethane | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| 1,1,2-Trichloroethane | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| 1,1,2-Trichloroethane | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| Chlorine | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | Eye and nose irritation; stomach discomfort |
| Benzene | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | Anemia; decrease in blood platelets; increased risk of cancer |
| Benzene | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | Anemia; decrease in blood platelets; increased risk of cancer |
| Benzene | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | Anemia; decrease in blood platelets; increased risk of cancer |
| Benzene | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | Anemia; decrease in blood platelets; increased risk of cancer |
| Chlorine | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | Eye and nose irritation; stomach discomfort |
| 2,4,5-TP | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| Chlorine | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | Eye and nose irritation; stomach discomfort |
| Chlorine | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | Eye and nose irritation; stomach discomfort |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Nov 30, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Nov 30, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Nov 30, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Nov 30, 2023 | Resolved | N/A |
| Chlorine | Monitoring | N/A | N/A | Sep 30, 2023 | Resolved | Eye and nose irritation; stomach discomfort |
| Chlorine | Monitoring | N/A | N/A | Sep 30, 2023 | Resolved | Eye and nose irritation; stomach discomfort |
| Chlorine | Monitoring | N/A | N/A | Sep 30, 2023 | Resolved | Eye and nose irritation; stomach discomfort |
| Chlorine | Monitoring | N/A | N/A | Sep 30, 2023 | Resolved | Eye and nose irritation; stomach discomfort |
| Chlorine | Monitoring | N/A | N/A | Sep 30, 2023 | Resolved | Eye and nose irritation; stomach discomfort |
| Arsenic | Health-Based | N/A | 0.031 | Sep 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.031 | Sep 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.031 | Sep 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.031 | Sep 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.031 | Sep 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | N/A |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.031 | Jun 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.031 | Jun 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.031 | Jun 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.031 | Jun 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.031 | Jun 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.032 | Mar 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.032 | Mar 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.032 | Mar 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.032 | Mar 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.032 | Mar 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.03 | Dec 31, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.03 | Dec 31, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.03 | Dec 31, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.03 | Dec 31, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.03 | Dec 31, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.026 | Sep 30, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.026 | Sep 30, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.026 | Sep 30, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.026 | Sep 30, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.026 | Sep 30, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.02 | Jun 30, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.02 | Jun 30, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.02 | Jun 30, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.02 | Jun 30, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.02 | Jun 30, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Groundwater Rule | Health-Based | N/A | N/A | Jun 28, 2022 | Resolved | N/A |
| Groundwater Rule | Health-Based | N/A | N/A | Jun 28, 2022 | Resolved | N/A |
| Groundwater Rule | Health-Based | N/A | N/A | Jun 28, 2022 | Resolved | N/A |
| Groundwater Rule | Health-Based | N/A | N/A | Jun 28, 2022 | Resolved | N/A |
| Groundwater Rule | Health-Based | N/A | N/A | Jun 28, 2022 | Resolved | N/A |
| Groundwater Rule | Health-Based | N/A | N/A | Jun 28, 2022 | Resolved | N/A |
| Groundwater Rule | Health-Based | N/A | N/A | Jun 28, 2022 | Resolved | N/A |
| Groundwater Rule | Health-Based | N/A | N/A | Jun 28, 2022 | Resolved | N/A |
| Groundwater Rule | Health-Based | N/A | N/A | Jun 28, 2022 | Resolved | N/A |
| Groundwater Rule | Health-Based | N/A | N/A | Jun 28, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Mar 31, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Mar 31, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Mar 31, 2022 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Mar 31, 2022 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Mar 31, 2022 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.022 | Mar 31, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.022 | Mar 31, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.022 | Mar 31, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.022 | Mar 31, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.022 | Mar 31, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.02 | Sep 30, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.02 | Sep 30, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.02 | Sep 30, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.02 | Sep 30, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.02 | Sep 30, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.039 | Jun 30, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.039 | Jun 30, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.039 | Jun 30, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.039 | Jun 30, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.039 | Jun 30, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Public Notice | Monitoring | N/A | N/A | Jun 21, 2021 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Jun 21, 2021 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Jun 21, 2021 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.03 | Mar 31, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.03 | Mar 31, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.03 | Mar 31, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.03 | Mar 31, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.03 | Mar 31, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |